Sustained response of recombinant human C1 esterase inhibitor for acute treatment of hereditary angioedema attacks
Open Access
- 1 April 2017
- journal article
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 118 (4) , 452-455
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Expert Perspectives on Hereditary Angioedema: Key Areas for Advancements in Care across the Patient JourneyAllergy & Rhinology, 2016
- US Hereditary Angioedema Association Medical Advisory Board 2013 Recommendations for the Management of Hereditary Angioedema Due to C1 Inhibitor DeficiencyThe Journal of Allergy and Clinical Immunology: In Practice, 2013
- Treatment with C1-esterase inhibitor concentrate in type I or II hereditary angioedema: A systematic literature reviewAllergy and Asthma Proceedings, 2013
- A focused parameter update: Hereditary angioedema, acquired C1 inhibitor deficiency, and angiotensin-converting enzyme inhibitor–associated angioedemaJournal of Allergy and Clinical Immunology, 2013
- WAO Guideline for the Management of Hereditary AngioedemaWorld Allergy Organization Journal, 2012
- Randomized placebo-controlled trial of the bradykinin B2 receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trialAnnals of Allergy, Asthma & Immunology, 2011
- Icatibant, a New Bradykinin-Receptor Antagonist, in Hereditary AngioedemaNew England Journal of Medicine, 2010
- Ecallantide for the Treatment of Acute Attacks in Hereditary AngioedemaNew England Journal of Medicine, 2010
- Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary AngioedemaNew England Journal of Medicine, 2010
- Hereditary AngioedemaNew England Journal of Medicine, 2008